|
EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Strategic Company Decision Korneuburg, Austria, 18 December 2023 – Marinomed Biotech AG (VSE:MARI) announces that the Company considers strategic options for its Carragelose business and has mandated an external advisor. A structured process was initiated, in which Marinomed and the advisor will start engaging with potential partners. The Company is continuously evaluating the business to enable the best possible future growth. Regulatory changes in the coming year will also be included in the evaluation, which are expected to have a positive impact on the Company's business, particularly with regard to Carragelose products. The evaluation process may include strategic partnerships and the consideration of transferring the Carragelose portfolio to a partner that could maximize its value enabling the Company to increase its focus on the Marinosolv platform. +++ End of the ad hoc announcement +++ End of Inside Information
18-Dec-2023 CET/CEST News transmitted by EQS Group AG. www.eqs.com |
| Language: | English |
| Company: | Marinomed Biotech AG |
| Hovengasse 25 | |
| 2100 Korneuburg | |
| Austria | |
| Phone: | +43 2262 90300 |
| E-mail: | office@marinomed.com |
| Internet: | www.marinomed.com |
| ISIN: | ATMARINOMED6 |
| WKN: | A2N9MM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market) |
| EQS News ID: | 1798437 |
| End of Announcement | EQS News Service |
|
|
1798437 18-Dec-2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
